MOTS-c

A mitochondrial-derived peptide — the metabolic entry in the federal six.

⚠ Safety first — read this before anything else on this page

Approval status: MOTS-c is not FDA-approved for any use. FDA has stated it identified no human exposure data for MOTS-c products. As of November 2026 it sits inside the draft enforcement-discretion policy — discretion is not approval.

What has actually happened to people:

No human adverse-event record has been found — and no human trials have been published in which one could appear. The absence of a harm record for MOTS-c is the absence of study, full stop.

What nobody knows: Everything human is unknown: safety, interactions, long-term effects. MOTS-c has a marketing literature and a rodent literature. It does not have a clinical one.

Get medical care now if:

Swelling of the lips or tongue, or trouble breathing, after any injection — call emergency services.
Unusual blood-sugar swings — shakiness, sweating, confusion, or readings far outside your normal range — if you monitor glucose; MOTS-c is sold on metabolic pathways and has never been tested alongside any diabetes drug.
An injection site that worsens over days, or a lump appearing one to several weeks later — the delayed infection pattern; it needs a clinician.

Who should stay away: Anyone managing diabetes or blood sugar with medication — the interaction has never been tested, and the population most likely to be harmed by an unmonitored metabolic effect is the population self-administering without glucose monitoring. Also: minors and anyone pregnant.

The product problem: Across more than 7,000 gray-market samples of all compounds, independent tester Finnrick Analytics reports roughly one in three fail basic expectations — wrong identity, wrong quantity, or contamination (February 2026). There is no MOTS-c-specific testing dataset.

Talk to a doctor who knows you are taking it. See our doctors directory. If you were harmed, report it to FDA MedWatch — your report is how the record gets built.

We don't publish doses, protocols, or sources — for any compound, ever. Our Legal Mandate.

What it is

A mitochondrial-derived peptide — the metabolic entry in the federal six.

What creators claim

Creators present MOTS-c as a mitochondrial/metabolic regulator tied to exercise pathways and metabolic flexibility. Dr. Froese devoted a full video to ’the truths about MOTS-c nobody is talking about’; Dr. Jones, DC argues most people are being misled about what it does (see Videos). Superpower opened preorders at $199/month — the highest price in its launch lineup (seller pricing, reported as market fact).

What the evidence shows

Human data is minimal — early and indirect; the mechanistic story (AMPK/mitochondrial signaling) comes overwhelmingly from preclinical work. No established human efficacy for any use.

Forms it is discussed in

Injectable is the discussed form.

Dangers on record

Near-zero human safety data is the standing caution; metabolic claims run far ahead of metabolic evidence. See Dangers.

Legal status (as of November 7, 2026)

Not FDA-approved. PCAC voted 7–5 for the Bulks List (July 2026); not on the list. One of the six in the October 30 enforcement-discretion policy (acetate, single-ingredient, conditions).